We investigated, in 36 healthy volunteers, the effects of prednisone and ketotifen on recovery of lymphocyte beta 2-adrenoceptor density (determined by (-)-125iodocyanopindolol binding) and responsiveness (assessed by lymphocyte cyclic AMP [cAMP] responses to 10 microM (-)-isoprenaline) after desensitization by the beta 2-agonist terbutaline. Terbutaline (3 X 5 mg/d) decreased lymphocyte beta 2-adrenoceptor density by approximately 40-50%; concomitantly, lymphocyte cAMP responses to 10 microM (-)isoprenaline were significantly reduced. After withdrawal of terbutaline beta 2-adrenoceptor, density and responsiveness gradually increased, reaching predrug levels after 4 d. Prednisone (1 X 100 mg orally) accelerated beta 2-adrenoceptor recovery; only 8-10 h after administration of the steroid beta 2-adrenoceptor density and cAMP responses to (-)isoprenaline had reached values not significantly different from pretreatment levels. Similar effects were obtained with ketotifen (2 mg; thereafter 2 X 1 mg/d for 4 d): 24 h after application of the drug beta 2-adrenoceptor density and cAMP responses to (-)-isoprenaline had reached pretreatment levels. Furthermore, ketotifen simultaneously applied with terbutaline completely prevented terbutaline-induced decrease in lymphocyte beta 2adrenoceptor density and responsiveness. Prednisone (1 X 100 mg orally) or ketotifen (2 mg; thereafter 2 X 1 mg/d for 2 d) had no significant influence on lymphocyte beta 2adrenoceptor density in healthy volunteers not pretreated with terbutaline, but shifted the ratio high-to-low affinity state of the lymphocyte beta 2-adrenoceptor toward high affinity […]
Introduction
A general mechanism of cellular adaptation is a decrease of responsiveness to pharmacological or hormonal stimulation with Portions ofthis work were presented in abstract form at the winter meeting of the British Pharmacological Society, London time. This phenomenon is referred to as desensitization, tachyphylaxis, or refractoriness. In vitro as well as in vivo studies have shown that in a variety oftissues, including human lymphocytes, long-term exposure to j3-adrenergic agonists resulted in an impaired f3-adrenergic function. This reduced responsiveness of(0adrenoceptors was consistently found to be due to a decreased density of receptors and/or to a diminished activity of the adenylate cyclase (for review see 1, 2) .
Agonists acting at f3-adrenergic receptors are used to treat asthma and other pulmonary dysfunctions. Human lymphocytes containing a homogeneous population of 02-adrenoceptors coupled to the adenylate cyclase are suitable tissues to study alterations of fl-adrenoceptor function in man (3; for references see 4 ). An agonist-induced decrease in fl-adrenoceptor number in lymphocytes from healthy as well as asthmatic subjects has been observed after prolonged treatment with fl-adrenergic agonists (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . The resulting tachyphylaxis may markedly limit the therapeutic efficacy of fl-adrenergic bronchodilator therapy in asthma (16) (17) (18) (19) .
Glucocorticoids seem to be involved in modulation of fladrenoceptor density and responsiveness (for review see 20) . It has been shown that glucocorticoids can increase (3-adrenergic responsiveness as indicated by enhanced inotropic responses in heart muscle (21) , enhanced vascular responses (22, 23) , and enhanced hepatic glucose production (24) after catecholamine stimulation. In addition, it has been shown in vitro as well as in vivo that agonist-induced desensitization ofthe fl-adrenoceptor/adenylate cyclase system can be attenuated (25) or rapidly reversed by glucocorticoids (26, 27) . Recently Bretz et al. (28) presented evidence that in rats, ketotifen (Zaditen; Sandoz Ltd., Basel, Switzerland), an antianaphylactic drug, can also prevent agonist-induced desensitization of the fl-adrenoceptors. In the present study, therefore, we compared in healthy volunteers the effects of prednisone and ketotifen on recovery of lymphocyte 32-adrenoceptor density (determined by (-)-'25iodocyanopindolol [ICYP]' binding) and responsiveness (assessed by lymphocyte cyclic AMP (cAMP) responses to 10 gM (-)-isoprenaline) after desensitization by the 32-agonist terbutaline.
Methods 36 healthy volunteers (26 males and 10 females), mean age 24.2±0.8 (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) yr, participated in the study after having given informed written consent. All were drug-free and had undergone physical examination to exclude asthma, chronic pulmonary disease, diabetes mellitus, hypertension, cardiac disease, and symptoms referable to the cardiovascular system. The experimental protocol is given in Fig. 1 . On two successive days before drug treatment, 30 ml heparin blood (500 I.U. heparin/l0 ml blood) for determination oflymphocyte 02-adrenoceptor density and cAMP responses to isoprenaline were withdrawn, with the subjects in sitting position. Thereafter, terbutaline (3 X 5 mg/d) was administered orally at 7 am., 3 p.m., and 9 p.m. for 9 d. Afterthe last dose ofterbutaline (7 a.m.) the subjects were divided into three age-matched and sex-matched groups. In the first group (n = 12), prednisone (1 X 100 mg per os at 9 a.m.) was administered; in the second group (n = 12), ketotifen (2 mg at 9 a.m., thereafter 2 X 1 mg/d at 7 a.m. and 7 p.m. for 4 d) was administered, while the third group (n = 12) did not receive any further treatment. Blood samples were collected at certain time intervals (indicated by the arrows in Fig. 1 ) during treatment with terbutaline and on four successive days after withdrawal of terbutaline. Lymphocytes were isolated from heparinized blood by the method of B6yum (29) , three times washed with phosphate-buffered saline (PBS), and finally resuspended in 12 mM Tris HCG, 154 mM NaCl buffer, pH 7.2, containing 30MgM phentolamine and 0.55 mM ascorbic acid. For determination of i#2-adrenoceptor density, lymphocytes (0.5-0.8 X 106 cells/tube) were incubated with 6-8 concentrations of ICYP ranging from 10 to 200 pM at 370C for 60 min in a total volume of250 M1. Incubation was terminated by diluting the entire reaction mixture with 10 ml of 10 mM Tris HCG, 154 mM NaCl buffer, pH 7.4 (37°C) followed by rapid filtration over Whatman GF/C filters (Whatman, Inc., Clifton, NJ). Each filter was washed with an additional 10 ml of buffer. The radioactivity of the wet filters was determined in a gamma counter (Gamma 4000; Beckman Instruments, Inc., Fullerton, CA) at an efficiency of -75%. Nonspecific binding ofICYP was defined as radioactivity bound which is not displaced by a high concentration of (±)-CGP 12177 (I ,M). Specific binding of ICYP was defined as total binding minus nonspecific binding; it usually amounted to 70% at 20 pM of ICYP. For determination of the cAMP content, lymphocytes were resuspended in PBS containing 0.25% bovine serum albumin and 100 gM theophylline. Lymphocytes (-1-2 X 106 cells/assay) were incubated either with PBS or with 10 gM (-)isoprenaline for 15 min at 37°C in a final volume of 330 Ml. Incubation was terminated by immersing the incubation tubes in boiling water for 5 min. After cooling, samples were centrifuged with 12,000 g for 10 min and the cAMP content was determined in IOO-Ml aliquots ofthe supernatant by the protein binding assay of Gilman (30) as modified by Schwabe and Ebert (31) . Details of the procedures have been described elsewhere (32) . Statistical evaluations. The experimental data given in the text, figures, and the table are means±SEM of n experiments. The maximal number of binding sites (B.) and the equilibrium dissociation constant (KD) for ICYP were calculated from plots according to Scatchard (33) . The significance of differences was estimated by t test. A P value < 0.05 was considered significant.
Results
The mean number of $2-adrenoceptors in lymphocytes of the 36 volunteers included in this study amounted to 797±66 ICYP binding sites/cell; the KD value for ICYP was 19.7±1.6 pM. Terbutaline (3 X 5 mg/d) led to a decrease in (#2-adrenoceptor density; only 2 d after application of the #2-agonist the j32-adreno- on this reduced level throughout the treatment period. Concomitantly, (-)-isoprenaline-(10 MM) evoked cAMP increases in lymphocytes were decreased to a similar extent. After withdrawal of terbutaline f32-adrenoceptor, density and (-)-isoprenaline-evoked cAMP increases recovered slowly, reaching predrug values after -4 d (Fig. 2) . The KD values for ICYP, however, did not change significantly during treatment or after withdrawal of terbutaline. Prednisone (1 X 100 mg orally) accelerated recovery of terbutaline-desensitized 02-adrenoceptor density and responsiveness; within 8-10 h after the administration ofthe glucocorticoid f2-adrenoceptor density and isoprenaline-induced cAMP increases had reached values that were not significantly different from predrug levels (Fig. 2 ). Terbutaline (3 X 5 mg/d) caused a rapid increase in heart rate by -20 beats/min after 1 d. During treatment heart rate declined slowly and reached predrug levels 4 d after cessation of the terbutaline treatment (Fig. 2 ). Note that immediately after prednisone application heart rate increased slightly, but significantly, before declining to predrug levels (Fig. 2) . Ketotifen (2 mg; thereafter, 2 X 1 mg/d) produced similar effects as prednisone. Administration ofthe drug after withdrawal of terbutaline led also to an acceleration of the recovery of ,3adrenoceptor density and responsiveness (Fig. 3 for cAMP responses to stimulation with 10 M1M isoprenaline ( Fig. 3 ).
In a further series of experiments we studied the effects of the simultaneous application of ketotifen (2 mg; thereafter, 2 X 1 mg/d) and terbutaline (3 X 5 mg/d) on 132-adrenoceptor density and responsiveness in lymphocytes. As shown in Fig. 4 , ketotifen completely prevented the terbutaline-induced decrease in lymphocyte f32-adrenoceptor density and 10 MuM isoprenalineevoked increase in cAMP.
Finally we studied the effects of prednisone (1 X 100 mg orally) or ketotifen (2 mg; thereafter, 2 X 1 mg/d for 2 d) on lymphocyte (32-adrenoceptors in healthy subjects not pretreated with terbutaline. Both drugs had no significant influence on the density of,32-adrenoceptors (Table I) . However, both drugs markedly affected inhibition of ICYP binding to lymphocyte membranes by the (3-agonist (-)-isoprenaline ( Figs. 5 and 6 ). In control membranes (-)-isoprenaline inhibited ICYP binding with shallow displacement curves; nonlinear regression analysis of these curves (34) revealed that isoprenaline binds to two affinity states of the lymphocyte (32-adrenoceptor, a high and a low affinity state. The dissociation constants for high affinity (KH) and low affinity state (KL) were: KH = 36.8±2.8 nM (n = 10) and KL = 1,215±133 nM (n = 10); the percentage of (3adrenoceptors in high affinity state amounted to 56.3±3.5% (n = 10). 16 h after prednisone the isoprenaline displacement curves were shifted to the left to lower concentrations (Fig. 5) ; KH was significantly decreased to 19.6±2.8 nM (n = 5; P < 0.01), while KL was slightly increased to 1,377±133 nM (n = 5); the percentage of receptors in high affinity state rose significantly from 56.3 to 72.0±7.8% (n = 5; P < 0.05).
Similar effects were obtained with ketotifen ( Fig. 6 ). 40 h after the first application of the drug, KH was decreased to 24.8±2.9 nM (n = 5; P < 0.01), while KL was slightly increased to 1,298±141 nM (n = 5); in addition, the percentage of fl- 10-6 1f M of 12 concentrations of (-)-iso-(-1-Isoprenatine prenaline, and specific binding was determined as described in the method section. "100%" inhibition refers to inhibition of specific binding by I uM (±)CGP 12177. *, control; o, 16 h after prednisone;
A, 40 h after prednisone. Means±SEM; n = 5. adrenoceptors in the high affinity state (69.5±5.9%; n = 5) was significantly higher than before ketotifen (P < 0.05).
Discussion
In this study, application of the f32-agonist terbutaline (3 X 5 mg/d) to healthy volunteers led to a decrease in lymphocyte (2- adrenoceptor density, which after only 2 d amounted to -40-50%. Concomitantly, isoprenaline-evoked increases in the intracellular level of cAMP (an index for functional responsiveness of lymphocyte 32-adrenoceptors) were decreased to a similar extent. After withdrawal of terbutaline (32- Prednisone (1 X 100 mg orally) markedly accelerated the recovery of i32-adrenoceptor density and responsiveness: only 8-10 h after administration of the glucocorticoid, both parameters had reached pretreatment levels. Similar effects of a rapid restoration of terbutaline-desensitized 132-adrenoceptors in lymphocytes from healthy as well as asthmatic subjects also have been described recently, after intravenous administration of 0-s methylprednisolone (12, 26) . In addition to glucocorticoids, ketotifen, an antianaphylactic drug, was also able to accelerate recovery of desensitized f32-adrenoceptors in lymphocytes. 24 h after addition of ketotifen i32-adrenoceptor, density and isoprenaline-evoked cAMP increases had reached predrug levels (cf. Fig. 3 ). Ketotifen, however, not only accelerated recovery of desensitized lymphocyte 132-adrenoceptors, but also prevented f2-adrenoceptor down-regulation; in the presence of ketotifen, terbutaline failed to alter significantly lymphocyte 132-adrenoceptor density and responsiveness (Fig. 4 ). This in vivo observation obtained in the human being is in good agreement with recently reported data in rats, where ketotifen completely abolished isoprenaline-induced desensitization of 32-adrenoceptors (28) .
The mechanism of this rapid restoration of desensitization of f-adrenoceptors by prednisone and ketotifen is not known at present. The possibility that this restoration might be caused by a percentage increase in B-lymphocytes, which may contain a higher g2-adrenoceptor density than T cells (35, 36) , can be excluded, since prednisone and ketotifen did not affect ,32-adrenoceptor density in lymphocytes that had not been pretreated with terbutaline (cf. Table I ). However, it has been shown that in various cells including human lymphocytes (for references see 1, 2), there is a reduction in f3-adrenoceptor density in the plasma membranes, when the cells are exposed for a period of time to f3-adrenoceptor agonists. Recent studies suggest that the downregulated f3-adrenoceptors are internalized by an endocytotic process (37) (38) (39) and are sequestered within the cells in a still unknown compartment. After removal of agonist the f3-adrenoceptors reappear at the cell surface. Hence, the accelerating effects of prednisone and ketotifen on recovery of desensitized lymphocyte r2-adrenoceptors described in the present study could be due to a reversal or inhibition of internalization of 13-adrenoceptors; another possibility could be an effect on the de novo synthesis of receptors. As discussed above (cf. While prednisone and ketotifen had no effects on lymphocyte B2-adrenoceptor density in the nondesensitized state, they markedly affected binding characteristics of the ,B-adrenoceptor agonist isoprenaline. 16 h after prednisone and 40 h after ketotifen the ratio high-to-low affinity state of the lymphocyte 2adrenoceptor had shifted toward high affinity state (cf. Figs. 5 and 6). Formation ofthe high affinity state ofthe /3-adrenoceptor seems to be essential for coupling receptor occupancy to the adenylate cyclase (41) . Davies and Lefkowitz (42) have recently shown in human neutrophils that exposure to glucocorticoids resulted in enhanced stabilization ofthe high affinity state ofthe fl-adrenoceptor as reflected in an enhanced adenylate cyclase activity. Our results confirm and extend these observations. They show that not only glucocorticoids, but also ketotifen, increase fl-adrenoceptor responsiveness by promoting the formation of the high affinity state of the (3-adrenoceptor and hence receptoradenylate cyclase coupling.
Our observations of a rapid restoration of down-regulated B3-adrenoceptor responsiveness by glucocorticoids are very consistent with clinical observations ofthe effects ofglucocorticoids in asthma. Asthmatic patients are frequently treated with r2adrenoceptor agonists, which might account for the decreased 13-agonist stimulated bronchodilation reported in subjects during treatment with (3-adrenergic drugs (16) (17) (18) (19) 43) . Glucocorticoids have been shown to restore responsiveness to adrenergic bronchodilators in tolerant patients (18, 44) and animals (45) . In addition, hydrocortisone can accelerate recovery from the desensitized state in isolated human airway smooth muscle (46) . According to our results, ketotifen exerts effects very similar to those of glucocorticoids. Thus, ketotifen may substitute glucocorticoids in asthmatic patients, where steroids are added when d3-agonist therapy is insufficient. In fact, a beneficial effect of ketotifen in the treatment of asthmatic patients has been described, since ketotifen administration leads to a reduction in the maintenance dose of oral steroids required by steroid-dependent asthmatics (47, 48) as well as to a reduction of the amount of bronchodilators (49) .
